Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy

References

• Kim TK, Gore SD, Zeidan AM. Epigenetic therapy in acute myeloid leukemia: current and future directions. Semin Hematol. 2015;52(3):172–183. doi: 10.1053/j.seminhematol.2015.04.003
   PubMed Web of Science ®Google Scholar
• Negrotto S, Ng KP, Jankowska AM, et al. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. Leukemia. 2012;26(2):244–254. doi: 10.1038/leu.2011.207
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670–2677. doi: 10.1200/JCO.2011.38.9429
   PubMed Web of Science ®Google Scholar
• Nieto M, Demolis P, Béhanzin E, et al. The European Medicines Agency review of decitabine (Dacogen) for the treatment of adult patients with acute myeloid leukemia: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist. 2016;21(6):692–700. doi: 10.1634/theoncologist.2015-0298
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Ravandi F, Liu-Dumlao T, et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood. 2012;120(24):4840–4845. doi: 10.1182/blood-2012-06-436055
   PubMed Web of Science ®Google Scholar
• Bender CM, Zingg JM, Jones PA. DNA methylation as a target for drug design. Pharm Res. 1998;15(2):175–187. doi: 10.1023/A:1011946030404
   PubMed Web of Science ®Google Scholar
• Diesch J, Zwick A, Garz AK, et al. A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers. Clin Epigenetics. 2016;8(71).
   PubMed Web of Science ®Google Scholar
• Gao S, Qiu H, Jin Z, et al. The clinical efficacy of the patients of acute myeloid leukemia and myelodysplastic syndromes treated with decitabine alone, combined with half or one couse of CAG regimen. Chin J Hematol. 2014;35(11):961–965.
   Google Scholar
• Lee JH, Jang JH, Park J, et al. A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome. Haematologica. 2011;96(10):1441–1447. doi: 10.3324/haematol.2011.046078
   PubMed Web of Science ®Google Scholar
• Cashen AF, Schiller GJ, O'Donnell MR, et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010;28(4):556–561. doi: 10.1200/JCO.2009.23.9178
   PubMed Web of Science ®Google Scholar
• Zhu Y, Qian SX, Li JY. Interpretation of decitabine treatment for elderly patients with acute myeloid leukemia: the multicenter, open-label, phase III clinical trial (registered trial DACO-016). Chin J Hematol. 2013;34(1):83–84.
   Google Scholar
• Scandura JM, Roboz GJ, Moh M, et al. Phase I study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood. 2011;118(6):1472–1480. doi: 10.1182/blood-2010-11-320093
   PubMed Web of Science ®Google Scholar
• Song LX, Xu L, Li X, et al. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia. Ann Hematol. 2012;91:1879–1886. doi: 10.1007/s00277-012-1550-y
   PubMed Web of Science ®Google Scholar
• Ye XN, Zhou XP, Wei JY, et al. Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms. Leuk Lymphoma. 2016;57(6):1311–1318. doi: 10.3109/10428194.2015.1091931
   PubMed Web of Science ®Google Scholar
• Podoltsev NA, Stahl M, Zeidan AM, et al. Selecting initial treatment of acute myeloid leukemia in older adults. Blood Rev. 2017;31(2):43–62. doi: 10.1016/j.blre.2016.09.005
   PubMed Web of Science ®Google Scholar
• Huang J, Hong M, Zhu Y, et al. Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia. Leuk Lymphoma. 2018;59(11):2570–2579. doi: 10.1080/10428194.2018.1443328
   PubMed Web of Science ®Google Scholar
• Lin D, Zhou C, Wei H, et al. Characteristics and treatment outcomes in 822 adult patients with acute myeloid leukemia: a single center experience. Chin J Hematol. 2014;35:1058–1064.
   Google Scholar
• Marbello L, Ricci F, Nosari AM, et al. Outcome of hyperleukocytic adult acute myeloid leukaemia: a single-center retrospective study and review of literature. Leuk Res. 2008;32(8):1221–1227. doi: 10.1016/j.leukres.2008.01.004
   PubMed Web of Science ®Google Scholar
• Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075–4083.
   PubMed Web of Science ®Google Scholar
• Prassek VV, Rothenberg-Thurley M, Sauerland MC, et al. Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older. Haematologica. 2018;103(11):1853–1861. doi: 10.3324/haematol.2018.191536
   PubMed Web of Science ®Google Scholar
• Marcucci G, Metzeler KH, Schwind S, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol, 2012, 30(7):742–750. doi: 10.1200/JCO.2011.39.2092
   PubMed Web of Science ®Google Scholar
• Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424–2433. doi: 10.1056/NEJMoa1005143
   PubMed Web of Science ®Google Scholar
• Gaidzik VI, Schlenk RF, Paschka P, et al. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood. 2013;121(23):4769–4777. doi: 10.1182/blood-2012-10-461624
   PubMed Web of Science ®Google Scholar
• Virijevic M, Karan-Djurasevic T, Marjanovic I, et al. Somatic mutations of socitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype. Radiol Oncol. 2016;50(4):385–393. doi: 10.1515/raon-2016-0044
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab O, Patel J, Levine RL. Clinical implications of novel mutations in epigenetic modifiers in AML. Hematol Oncol Clin North Am. 2011:25 (6):1119–1133. doi: 10.1016/j.hoc.2011.09.013
   PubMed Web of Science ®Google Scholar
• Li J, Chen Y, Zhu Y, et al. Efficacy and safe of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia. Oncotarget. 2015;6(8):6448–6458.
   PubMedGoogle Scholar
• Hiller JK, Schmoor C, Gaidzik VI, et al. Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy. Ann Hematol. 2017;96(4):559–565. doi: 10.1007/s00277-016-2912-7
   PubMed Web of Science ®Google Scholar